Ownership
Private
Employees
~10
Therapeutic Areas
Ophthalmology
Stage
Phase 3
Modalities
Small moleculeMedical devices

Epion Therapeutics General Information

Developing minimally-invasive epithelium-on corneal cross-linking treatment. Phase 2 trial completed successfully showing halting of keratoconus progression. Phase 3 trials initiated in 2023.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

EpiSmart
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Epion Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Epion Therapeutics Funding

Deal TypeDateAmountStatusStage
Later Stage VCSep 30, 2022$32.0MCompletedPhase 3
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Epion Therapeutics's complete valuation and funding history, request access »